MIRA Pharmaceuticals, Inc.
MIRA
$0.78
$0.000.61%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.26M | 7.86M | 8.77M | 5.02M | 5.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.40M | 9.79M | 10.49M | 7.11M | 7.87M |
| Operating Income | -9.40M | -9.79M | -10.49M | -7.11M | -7.87M |
| Income Before Tax | -9.48M | -9.81M | -10.44M | -6.86M | -7.77M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.48 | -9.81 | -10.44 | -6.86 | -7.77 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.48M | -9.81M | -10.44M | -6.86M | -7.77M |
| EBIT | -9.40M | -9.79M | -10.49M | -7.11M | -7.87M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.38 | -1.44 | -1.52 | -1.52 | -0.48 |
| Normalized Basic EPS | -0.17 | -0.20 | -0.25 | -0.26 | -0.30 |
| EPS Diluted | -1.38 | -1.44 | -1.52 | -1.52 | -0.48 |
| Normalized Diluted EPS | -0.17 | -0.20 | -0.25 | -0.26 | -0.30 |
| Average Basic Shares Outstanding | 144.06M | 119.03M | 93.73M | 69.47M | 65.26M |
| Average Diluted Shares Outstanding | 144.06M | 119.03M | 93.73M | 69.47M | 65.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |